Rockwell Medical Inc. (NASDAQ:RMTI) shares saw unusually-high trading volume on Tuesday . Approximately 451,331 shares traded hands during trading, an increase of 87% from the previous session’s volume of 240,748 shares.The stock last traded at $7.13 and had previously closed at $7.51.

Separately, Zacks Investment Research upgraded shares of Rockwell Medical from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 5th. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $10.17.

The stock has a 50-day moving average of $7.73 and a 200-day moving average of $7.81. The stock’s market capitalization is $365.83 million.

Rockwell Medical (NASDAQ:RMTI) last issued its quarterly earnings results on Monday, August 8th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.01. During the same period in the previous year, the firm earned ($0.05) EPS. The firm earned $12.50 million during the quarter, compared to analysts’ expectations of $13.86 million. Rockwell Medical’s quarterly revenue was down 3.5% on a year-over-year basis. Equities research analysts forecast that Rockwell Medical Inc. will post ($0.31) earnings per share for the current year.

Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.